This is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury. Eligible patients will receive KP-100 0.6 mg/body by intrathecal administration once per week for a total of 5 doses and will be followed for approximately 24 weeks after the first dose.
Inclusion Criteria:
Exclusion Criteria:
hayata@kringle-pharma.com'+81-6-7653-6728
y.abe@kringle-pharma.com+81-6-7653-6728
Iizuka, Fukuoka 820-8508, Japan
+81-948-24-7500
Bibai, Hokkaido 072-0015, Japan